Top mais recente Cinco nervocure notícias Urban
Top mais recente Cinco nervocure notícias Urban
Blog Article
about us our therapy our products our pipeline investor relations careers news and media patient-forward contact us
Continuar comprando Finalizar compra Ir de modo a este carrinho Não foi possível adicionar o produto ao carrinho
Are you sure you'd like to continue? This link will navigate you to an external website outside of Novocure.com. Cancel Continue
Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
NovoCure has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, July 25th, 2024 based off last year's report dates. Learn more on NVCR's earnings history.
Continuar comprando Finalizar adquire Ir de modo a o carrinho Não foi possível adicionar o produto ao carrinho
Não perca Muito mais tempo! Clique agora para ativar seu Abatimento especial e adquira este Nervocure diretamente do sitio oficial.
investor relations home stock information corporate presentation SEC filings press releases corporate governance
TTFields’ unique mechanism of action underscores key points related to its effective administration and clinical benefit. Unlike chemotherapeutic agents, TTFields are only active while the arrays are affixed to the scalp and the alternating electric fields are generated between the transducer arrays. As a loco-regional and non-invasive targeted therapy, TTFields has the benefit of avoiding systemic adverse events associated with chemotherapy and targeted systemic therapies. The primary treatment-associated adverse event experienced by some patients with TTFields is skin irritation below the arrays, which is predictable and easily manageable in the majority of cases.
Figure 2: Effects of TTFields on replicating cells. TTFields exert directional forces on polar microtubules and interfere with the assembly of the normal mitotic spindle and subsequently trigger mitotic cell death.
Já nervocure ficou desesperado e isolado por causa da dor de que nunca vai embora? Costuma ficar utilizando raiva, ansioso e triste porque nao consegue resolver o problema? Deixou do fazer coisas de que você gosta por causa da dor?
Simulations and modelling are the primary tools for obtaining these essential data (Fig. 4). Simulation-based studies using realistic head models have shown that TTFields effectively penetrate the brain and tumour tissue. The field distribution is heterogeneous and depends on the anatomy of the individual patient, the physical properties of the various tissue types and the location of the tumour10. The position of arrays can therefore be optimized using the NovoTAL System to deliver maximal field intensities to the tumour region of the individual patient10,11.
Enter your email address below to receive the latest news and analysts' ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.
Unlike systemic cancer therapies, TTFields only act against rapidly dividing cancer cells while the transducer arrays are adhered to the scalp and TTFields are active. Consequently, the average daily usage of the device (or treatment compliance) is a crucial component of clinical benefit.